TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

183 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

135 studies on the map

Acceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease — Children's Hospital Los Angeles, Los AngelesStudy of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder — University of Alabama at Birmingham, HuntsvilleA Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants — Emory University, AtlantaA Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) — Harmonex Neuroscience Research, DothanA Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) — Mayo Clinic in Arizona, ScottsdaleA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) — University of Alabama at Birmingham, BirminghamAlpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response — Yale University, New HavenA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease — Cedars Sinai Medical Center, Los AngelesA Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) — Noble Clinical Research, TucsonA Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease — Peak Gastroenterology Associates - Colorado Springs-Site Number: 8400039, Colorado SpringsA Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis — Del Sol Research Management, LLC - Site Number: 8400012, TucsonA Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD) — University of Alabama at Birmingham, BirminghamStudy of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans — Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine,, West HavenFeasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department — University of Kansas Strawberry Hill Campus, Kansas CityEffects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression — Laureate Institute for Brain Research, TulsaACT for Individuals With MNCD and Their Care Partners — Texas Tech University Plaza Building, LubbockCSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes — VA Long Beach Healthcare System, Long Beach, CA, Long BeachEscalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaRCT of Psilocybin-assisted CBT for Depression — UCLA Semel Institute, Los AngelesA Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease — Phoenix Children's Hospital, PhoenixA Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With AION-301 Administered by Intravenous Infusion Compared With Placebo Administered by Intravenous Infusion Investigational Intervention in Participants Aged 35 to 75 Years of Age With Chronic Kidney Disease (CKD) — SouthCoast Research Center, Inc., MiamiNebulized Ketamine for the Treatment of Major Depressive Disorder — Maimonides Medical Center, BrooklynAn Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis — Erick H. Alayo Medical Corporation - Gastro SB Clinic, Chula VistaA Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder — IMA Clinical Research Phoenix, PhoenixThe Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease — University of Alabama at Birmingham- Site Number : 8400003, BirminghamA Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder — UAB Psychiatry and Behavioral Neurology, BirminghamDBS for Depression — Zucker Hillside Hospital, QueensAutologous Stem Cell Transplantation for Crohn's Disease — UPMC Prebyterian- Adult Gastroenterology, PittsburghA Study of Brenipatide in Adult Participants With Major Depressive Disorder — Accellacare - Moorpark, MoorparkArginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease — Children's Healthcare fo Atlanta at Hughes Spalding, AtlantaCreatine for Depressed Male and Female Methamphetamine Users — Montana State University College of Nursing (Missoula campus), MissoulaAn Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab — National Institutes of Health Clinical Center, BethesdaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease — UCSD Medical Center, La JollaAdjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression — The University of Texas Health Science Center at Houston, HoustonA Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis — Childrens Hospital of Los Angeles, Los AngelesTesting the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease — Weill Cornell Medicine, New YorkA Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function — Floridian Clinical Research, LLC, Miami LakesA Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease — Phoenix Children's Hospital /ID# 255766, PhoenixA Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend) — Lighthouse Psychiatry, GilbertTreatment of Moderate to Severe Refractory Crohn's Disease — Mayo Clinic Arizona, ScottsdaleA Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis — Phoenix Children's Hospital /ID# 273015, PhoenixOpen-label Extension Study of Zigakibart in Adults With IgA Nephropathy. — Colorado Kidney Care Nephrology, DenverRH Genotype Matched RBC Transfusions — Children's Hospital of Philadelphia, PhiladelphiaPrefrontal Glutamatergic Modulation by NAC and MBCT for Depression in Youth — University of Cincinnati, Department of Psychiatry and Behavioral Neuroscience, CincinnatiPharmacologic Augmentation of TMS for Depression With D-serine — McLean Hospital, BelmontNeural Response to Inflammatory Challenge in Major Depressive Disorder — Laureate Institute for Brain Research, TulsaAn Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis — Onyx Clinical Research - Site Number: 8400021, PeoriaThe Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder — Athinoula A. Martinos Center for Biomedical Imaging, CharlestownClinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol — Clinical Research Site, ChinoTransplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease — University of California, Los Angeles, Los AngelesA Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis — Children's Healthcare of Atlanta, AtlantaSotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease — Stanford University Medical Center, StanfordA Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease — Digestive Health Specialists of the Southeast, DothanA Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, OceansideOpen-Label Psilocybin Study in Transdiagnostic Population — Connecticut Mental Health Center - Yale School of Medicine, New HavenNBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, HuntsvilleStudy to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD — Northwestern Memorial Hospital, ChicagoBone in CKD Alkali Response (BICARb Pilot Trial) — Albert Einstein College of Medicine, The BronxUse of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use — 46 Centerra Parkway, Suite 300, Office #333S, LebanonCannabidiol in Sickle Cell Disease — Icahn School of Medicine at Mount Sinai, ManhattanMirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study — Digestive Health Specialists, DothanMirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight — Digestive Health Specialists, DothanA Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder — University of Alabama at Birmingham, BirminghamNBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, ChinoGene Editing For Sickle Cell Disease — St. Jude Children's Research Hospital, MemphisLong-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, HuntsvilleSafety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease — Quotient Sciences Sea View, MiamiStudy of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease — Site # 8400006, AtlantaEnhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33) — UC San Diego, San DiegoSAfety of Regional Citrate Anticoagulation (SARCA Study) — John L. McClellan Memorial Veterans' Hospital, Little RockLow Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy — Pine Rest Christian Mental Health Services, Grand RapidsEASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) — Apogee Clinical Research, HuntsvillePhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms — University of Alabama at Birmingham, BirminghamA Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008) — Digestive Health Specialists ( Site 5064), DothanEvaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder — Vanda Investigational Site, PhoenixA Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease — Cedars Sinai Medical Center, Los Angeles"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" — Scottsdale Research Institute, PhoenixPatient-driven Management of BP in CKD — Iowa City VA Health Care System, Iowa City, IA, Iowa CityStudy to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD — New York University Langone Health, New YorkA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort — Research Site, GlendaleBZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants — Ohio State University Comprehensive Cancer Center, ColumbusA Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease — Floridian Clinical Research, Miami LakesPersonalized Ultrasonic Brain Stimulation for Depression (R61) — University of Utah, Salt Lake CityR-3750 in Patients With Mild to Moderate Ulcerative Colitis — Amicis Research Center, ValenciaA Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder — CI Trials, BellflowerA Ketamine-assisted Group Therapy Intervention for Spanish-speaking Adults With Depression — Massachusetts General Hospital, Chelsea, ChelseaA Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia — Univ of Alabama Birmingham, BirminghamA Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease — University of Alabama at Birmingham, BirminghamA Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease — Clinnova Research, AnaheimBreakthrough - T1DM and Chronic Kidney Disease — The University of Chicago, ChicagoPartial Stem Cell Transplant for Sickle Cell Disease From Matched Donors — National Institutes of Health Clinical Center, BethesdaStudy to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaHematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies — Boston Children's Hospital, BostonCrohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease — UCSF Benioff Children's Hospital - Oakland /ID# 262217, OaklandBeta-Hydroxybutyrate Feasibility Treating IBD — University of Texas at Austin, AustinPsilocybin in Chronic Low Back Pain and Depression — Johns Hopkins University School of Medicine, BaltimoreStudy of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis — Xencor Investigative Site, ScottsdaleMulticenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients — Harmonex Neuroscience Research, DothanA Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD) — Phoenix Childrens Hospital, PhoenixSCD Stem Cell Mobilization and Apheresis Using Motixafortide — University of Alabama at Birmingham, BirminghamA Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) — University Of Alabama, BirminghamPattern Separation in Major Depressive Disorder — New York State Psychiatric Institute (NYSPI), New YorkGamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression — Wells Medicine, HoustonAn Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease — Onyx Clinical Research - Site Number: 8400021, PeoriaA Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease — AZ Gastro Care, ChandlerStudy of Panobinostat (LBH589) in Patients With Sickle Cell Disease — Augusta University, AugustaA Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease — University of Alabama Birmingham, BirminghamSympatholysis in Chronic Kidney Disease — Atlanta VA Medical Center, DecaturNeuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder — National Institutes of Health Clinical Center, BethesdaReduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders — Yale School of Medicine, New HavenA Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD) — Memorial Healthcare System, HollywoodA Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis — Digestive Health Specialists of the Southeast (Gastroenterology Associates of Dothan) - Dothan, DothanMechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression — National Institutes of Health Clinical Center, BethesdaBiomarker-guided rTMS for Treatment Resistant Depression — Stanford University, StanfordShingrix in Renal Transplant Recipients — University of Colorado Anschutz, AuroraA Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease — Uni of Alabama at Birmingham, BirminghamLow Dose IL-2 for the Treatment of Crohn's Disease — Boston Children's Hospital, BostonA Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China — Renal Consultants Medical Group, Granada HillsExtension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011) — Connecticut Clinical Research Institute ( Site 0297), BristolA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) — Phoenix Childrens Hospital, PhoenixStudy of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma — Stanford, Palo AltoMethylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease — St. Jude Children's Research Hospital, MemphisPCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study — Mood Institute, MilfordPsilocybin to Treat Depression in Spinal Cord Injury — James J. Peters Department of Veterans Affairs Medical Center, The BronxA Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD) — University of South Alabama (USA) Physicians Group, MobileRuxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease — Children's Hospital of Colorado, AuroraDelayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants — UCLA, Los AngelesA Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure — Research Site, FairhopeE-Mindfulness Approaches for Living After Breast Cancer — Mayo Clinic Hospital in Arizona, PhoenixAdia Med of Winter Park LLC Chronic Kidney Disease Research Study — Adia Med Of Winter Park, Winter ParkA Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006) — Panax Clinical Research ( Site 0003), Miami LakesStudy to Evaluate the Fecal Microbiota Transplantation (FMT) in the Treatment of Ulcerative Colitis — The University of Texas Health Science Center at Houston, HoustonNMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits — Washington University School of Medicine, St LouisHaploidentical Transplantation With Pre-Transplant Immunosuppressive Therapy for Patients With Sickle Cell Disease — City of Hope Medical Center, DuarteImpact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile — Deepa Valvi, Lexington

Showing the 150 nearest — narrow your filters for fewer, closer studies.